Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

High-throughput hacking of the methylation patterns in breast cancer by in vitro transcription and thymidine-specific cleavage mass array on MALDI-TOF silico-chip.

Radpour R, Haghighi MM, Fan AX, Torbati PM, Hahn S, Holzgreve W, Zhong XY.

Mol Cancer Res. 2008 Nov;6(11):1702-9. doi: 10.1158/1541-7786.MCR-08-0262.

2.

ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Baker JC Jr, Ostrander JH, Lem S, Broadwater G, Bean GR, D'Amato NC, Goldenberg VK, Rowell C, Ibarra-Drendall C, Grant T, Pilie PG, Vasilatos SN, Troch MM, Scott V, Wilke LG, Paisie C, Rabiner SM, Torres-Hernandez A, Zalles CM, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1884-90. doi: 10.1158/1055-9965.EPI-07-2696.

3.

Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.

Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK.

Clin Cancer Res. 2008 May 1;14(9):2664-72. doi: 10.1158/1078-0432.CCR-07-1232.

4.

Cytosine methylation profiling of cancer cell lines.

Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, van den Boom D.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4844-9. doi: 10.1073/pnas.0712251105. Epub 2008 Mar 19.

5.

Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF.

Bean GR, Bryson AD, Pilie PG, Goldenberg V, Baker JC Jr, Ibarra C, Brander DM, Paisie C, Case NR, Gauthier M, Reynolds PA, Dietze E, Ostrander J, Scott V, Wilke LG, Yee L, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Tlsty TD, Seewaldt VL.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6834-41.

6.

Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S.

Neoplasia. 2007 Jul;9(7):569-77.

7.

Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.

Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R.

Life Sci. 2007 Jul 4;81(4):280-7. Epub 2007 May 25.

PMID:
17599361
8.

Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.

Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS.

J Mol Diagn. 2007 Jul;9(3):305-14.

9.

Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet.

Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, Albertsen H, Potter JD, Samowitz WS.

Carcinogenesis. 2007 Aug;28(8):1672-9. Epub 2007 Apr 21.

10.

TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.

Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS.

Hum Pathol. 2007 Apr;38(4):614-20. Epub 2007 Jan 31.

PMID:
17270239
11.

Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.

Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC Jr, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):50-6.

12.
13.

Long-term raloxifene in a woman at high risk for breast cancer.

Bean GR, Kimler BF, Seewaldt VL.

N Engl J Med. 2006 Oct 12;355(15):1620-2. No abstract available.

14.

DNA methylation profiles of female steroid hormone-driven human malignancies.

Campan M, Weisenberger DJ, Laird PW.

Curr Top Microbiol Immunol. 2006;310:141-78. Review.

PMID:
16909910
15.

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW.

Nat Genet. 2006 Jul;38(7):787-93. Epub 2006 Jun 25.

PMID:
16804544
17.

DNA hypermethylation in breast cancer and its association with clinicopathological features.

Li S, Rong M, Iacopetta B.

Cancer Lett. 2006 Jun 18;237(2):272-80. Epub 2005 Jul 18.

PMID:
16029926
18.

Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.

Bean GR, Scott V, Yee L, Ratliff-Daniel B, Troch MM, Seo P, Bowie ML, Marcom PK, Slade J, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Baker JC Jr, Wilke LG, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8.

19.

CpG island methylator phenotype in cancer.

Issa JP.

Nat Rev Cancer. 2004 Dec;4(12):988-93. doi: 10.1038/nrc1507. Review.

PMID:
15573120
20.

Hypermethylation in histologically distinct classes of breast cancer.

Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5998-6005.

Supplemental Content

Support Center